Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Pentadecanoic Acid (C15:0) Presented as a Leading Longevity-Enhancing Molecule at World's Most Prestigious Anti-Aging Science Conference


News provided by

Fatty15

Sep 17, 2024, 12:00 ET

Share this article

Share toX

Share this article

Share toX

C15:0 outranks rapamycin and metformin in clinically relevant benefits to slow aging and delay the onset of chronic diseases

COPENHAGEN, Denmark, Sept. 17, 2024 /PRNewswire-PRWeb/ -- In a groundbreaking development in the field of geroprotection, recent clinical trials and studies identify pentadecanoic acid (C15:0) as a powerful agent in promoting longevity and healthy aging, outranking traditional longevity treatments such as rapamycin and metformin. At the 11th Aging Research and Drug Discovery Meeting, Dr. Nicholas J. Schork, a leader at the National Institute of Health-funded Longevity Consortium, shared C15:0's newly discovered role as an essential fatty acid to support both healthspan and lifespan. Further, Dr. Schork discussed its potential to outpace traditional longevity treatments, marking a significant evolution in our understanding of aging and age-related diseases.

Aging Hallmarks and the Role of C15:0

Geroprotection involves targeting the biological hallmarks of aging to delay the onset of age-related diseases and promote a longer, healthier life. C15:0, also known as pentadecanoic acid, influences several key aging hallmarks, including cellular senescence and mitochondrial dysfunction.

Studies reveal that C15:0 stabilizes cell membranes, reduces inflammation, and enhances mitochondrial function—all critical in slowing the aging process. Unlike traditional geroprotectors, C15:0 works at the cellular level to target multiple hallmarks of aging, restoring balance and resilience and offering a holistic approach to aging intervention.

"The breadth of evidence for its health benefits is what makes C15:0 so compelling. Very few, if any, candidate geroprotectors have been subjected to the same level of rigor in a wide variety of settings—cell-based studies, studies involving non-human species, human population studies, clinical trials, pharmacology studies, and more—and all have resulted in very positive findings," said Dr. Schork.

A Leading Expert in Aging Research

Dr. Nicholas J. Schork has been a pioneering figure in aging research. He has authored over 600 peer-reviewed scientific papers and has been involved in numerous collaborative and consortium-related research projects. As the Principal Investigator of the Longevity Consortium, Dr. Schork is at the forefront of identifying and characterizing factors that contribute to human longevity. The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), conducts and supports genetic, biological, clinical, behavioral, social, and economic research on aging and the challenges and needs of older adults.

What Makes C15:0 a Standout Geroprotector

At his presentation at the ARDD Symposium, entitled "Pentadecanoic acid (C15:0) as a Geroprotector: Evolution, Aging Hallmarks, and a Preponderance of Evidence," Dr. Schork emphasized the remarkable breadth of evidence supporting C15:0 as a promising geroprotector.

"C15:0 has many advantages. Its health benefits can be easily assessed by physicians using routine health panels, safely administered as a promising candidate geroprotector, and is known to have broad effects across multiple phenotypes and against multiple aging-associated conditions. Because of this, C15:0 is likely to be a core component of longevity medicine programs," shared Dr. Schork.

The extensive validation across diverse research domains sets C15:0 apart from other longevity-enhancing nutrients. While many compounds may show promise in isolated studies, C15:0's consistent positive outcomes across a spectrum of rigorous scientific investigations solidify its standing as a leading candidate in the field of geroprotection.

C15:0 vs. Rapamycin and Metformin

The preponderance of evidence from recent trials positions C15:0 ahead of established geroprotectors like rapamycin and metformin. Numerous studies have demonstrated that C15:0 supports longevity-enhancing activities and improved quality of life by targeting the root causes of aging at the molecular level.

One notable study compares the efficacy of C15:0 with rapamycin and metformin, two well-known agents in the longevity space. The results are striking: C15:0 stands out by targeting the root causes of aging at the cellular level. While drugs like rapamycin focus on inhibiting pathways associated with aging, C15:0 both inhibits these processes and enhances cellular resilience by strengthening cell membranes and boosting mitochondrial function, essential for maintaining cell health as we age.

Fixing C15:0 Nutritional Deficiencies to Slow Aging

Moreover, a newly discovered nutritional C15:0 deficiency syndrome called Cellular Fragility Syndrome has been shown to cause ferroptosis, a newly discovered form of cell death that accelerates aging and the onset of chronic aging-associated conditions.

Laboratory and clinical trials show that fixing nutritional C15:0 deficiencies can reverse Cellular Fragility Syndrome and ferroptosis, including improved red blood cell, liver, metabolic, and gut health, providing a more comprehensive approach to healthy aging compared to the singular mechanisms of traditional drugs.These findings suggest that C15:0 could be a more effective and safer option for those seeking to prolong life and maintain vitality.

A New Era in Longevity Research

As research into C15:0 continues to expand, its status as a leading geroprotector becomes increasingly clear. The scientific community is now exploring the broader implications of C15:0 in the context of personalized medicine and aging interventions, with the potential to revolutionize how we approach aging and age-related diseases.

"With the wealth of evidence now available, it's time to rethink our strategies for promoting longevity," added Dr. Schork. "C15:0 represents a new frontier in aging research, offering hope for more effective and accessible ways to support both our healthspan and lifespan."

About Seraphina Therapeutics. Inc.
Seraphina Therapeutics, Inc. is a health and wellness company dedicated to advancing global health through the discovery of essential fatty acids and micronutrient therapeutics. Dr. Venn-Watson's initial discoveries on the importance of C15:0, which were made while helping to continually improve the health of aging dolphins, is a featured TEDx talk. Fatty15 has been awarded the 2024 Overall Supplement of the Year by Mindful Awards, is a 2024 FastCompany World Changing Idea in Wellness, and a top 2024 Healthy Aging Ingredient by NutraIngredients.

With its team of industry-leading scientists, Seraphina Therapeutics challenges long-held approaches to nutrition, enabling the creation of novel health products designed to support quality of life. For more information, please visit DiscoverC15.com and fatty15.com.

For media requests contact [email protected]

Media Contact

Seraphina Therapeutics, Inc., Fatty15, 619-407-9225, [email protected], fatty15.com

SOURCE Fatty15

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.